Silence Therapeutics plc
SLN
$13.55
-$0.14-1.02%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -97.74% | -96.97% | -98.71% | 29.49% | 23.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.74% | -96.97% | -98.71% | 29.49% | 23.54% |
| Cost of Revenue | -98.50% | -98.10% | -98.18% | -80.01% | -39.46% |
| Gross Profit | -97.53% | -96.42% | -98.91% | 169.98% | 72.39% |
| SG&A Expenses | -18.35% | -22.36% | -16.88% | -8.93% | 3.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.31% | -27.50% | -10.76% | 27.09% | 45.59% |
| Operating Income | 10.32% | 0.86% | -65.97% | -26.23% | -56.13% |
| Income Before Tax | 23.86% | -5.78% | -99.26% | 1.74% | -81.66% |
| Income Tax Expenses | -99.48% | -98.17% | -98.70% | -96.56% | -94.23% |
| Earnings from Continuing Operations | 24.23% | -4.91% | -95.57% | 14.04% | -58.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.23% | -4.91% | -95.57% | 14.04% | -58.30% |
| EBIT | 10.32% | 0.86% | -65.97% | -26.23% | -56.13% |
| EBITDA | 10.27% | 0.79% | -66.85% | -26.54% | -56.93% |
| EPS Basic | 24.35% | -4.42% | -93.41% | 18.64% | -39.33% |
| Normalized Basic EPS | 22.70% | -3.43% | -94.20% | 6.96% | -58.08% |
| EPS Diluted | 24.35% | -4.42% | -93.41% | 18.64% | -39.33% |
| Normalized Diluted EPS | 22.70% | -3.43% | -94.20% | 6.96% | -58.08% |
| Average Basic Shares Outstanding | 0.10% | 0.36% | 2.13% | 6.93% | 13.08% |
| Average Diluted Shares Outstanding | 0.10% | 0.36% | 2.13% | 6.93% | 13.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |